On September 10, 2026 BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, reported that two abstracts featuring GLIX1 have been accepted for presentation, including one selected for oral presentation highlighting the preclinical efficacy of GLIX1 in orthotopic glioblastoma models, at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026), which will be held September 24-27 in Rome, Italy.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are very pleased to be presenting our pre-clinical data and clinical trial design at EANO, Europe’s premier neuro-oncology conference," stated Philip Serlin, Chief Executive Officer of BioLineRx. "Notably, our preclinical data demonstrating the potent anti-tumor effect of GLIX1 in GBM across multiple in-vivo studies, including two orthotopic cell-derived xenograft GBM models as well as a temozolomide-resistant patient derived xenograft model, will be featured in a mini-oral presentation. Together with our e-poster highlighting the design of our first-in-human Phase 1/2a clinical trial, which is actively enrolling patients, these presentations showcase the breadth and momentum of the GLIX1 program."
Abstract Details:
Title: GLIX1, a TET2 activator targeting the DNA damage response: Potent anti-tumor activity across multiple orthotopic glioblastoma models
Presenter: Dr. Adam Robertson, Ph.D., Chief Scientific Officer, Hemispherian AS
Session type: Mini Oral Session
Session number/title: MO02-Microenvironment, preclinical models and treatment resistance
Presentation Date/time: Friday, September 25, 2026, 6:00-6:30pm CEST (12:00-12:30pm EDT)
Summary: GLIX1, an oral TET2 activator targeting the DNA damage response, showed high in vitro potency across cancer cell lines and increased TET2-dependent 5hmC generation in biochemical assays, in vitro, and in vivo xenograft models. In mice, GLIX1 achieved brain exposures at 68-85% of plasma levels, supporting CNS penetration. In GBM genomic 5hmC is markedly reduced versus healthy brain tissue, reflecting impaired TET2 activity. Together, these data provide a strong rationale for GLIX1 treatment of GBM, one of the most aggressive cancers where more effective treatments are desperately needed.
(Press release, BioLineRx, SEP 10, 2026, View Source [SID1234670716])